|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sadick M, Schoenberg SO, Hoermann K and
Sadick H: Aktuelle Standards und Fortschritte in der onkologischen
Bildgebung von Kopf-Hals-Tumoren. Laryngorhinootologie. 91(Suppl
1): S27–S47. 2012. View Article : Google Scholar
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kademani D: Oral cancer. Mayo Clin Proc.
82:878–887. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bonner JA, Harari PM, Giralt J, Cohen RB,
Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al:
Radiotherapy plus cetuximab for locoregionally advanced head and
neck cancer: 5-year survival data from a phase 3 randomised trial,
and relation between cetuximab-induced rash and survival. Lancet
Oncol. 11:21–28. 2010. View Article : Google Scholar
|
|
6
|
Forastiere A, Koch W, Trotti A and
Sidransky D: Head and neck cancer. N Engl J Med. 345:1890–1900.
2001. View Article : Google Scholar
|
|
7
|
Maier H, Dietz A, Gewelke U, Heller WD and
Weidauer H: Tobacco and alcohol and the risk of head and neck
cancer. Clin Investig. 70:320–327. 1992.PubMed/NCBI
|
|
8
|
Lewin F, Norell SE, Johansson H,
Gustavsson P, Wennerberg J, Biörklund A and Rutqvist LE: Smoking
tobacco, oral snuff, and alcohol in the etiology of squamous cell
carcinoma of the head and neck: A population-based case-referent
study in Sweden. Cancer. 82:1367–1375. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Viswanathan H and Wilson JA: Alcohol - the
neglected risk factor in head and neck cancer. Clin Otolaryngol
Allied Sci. 29:295–300. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fakhry C, Westra WH, Li S, Cmelak A, Ridge
JA, Pinto H, Forastiere A and Gillison ML: Improved survival of
patients with human papillomavirus-positive head and neck squamous
cell carcinoma in a prospective clinical trial. J Natl Cancer Inst.
100:261–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gillison ML, Koch WM, Capone RB, Spafford
M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, et
al: Evidence for a causal association between human papillomavirus
and a subset of head and neck cancers. J Natl Cancer Inst.
92:709–720. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trizna Z and Schantz SP: Hereditary and
environmental factors associated with risk and progression of head
and neck cancer. Otolaryngol Clin North Am. 25:1089–1103.
1992.PubMed/NCBI
|
|
13
|
Hecht F and Hecht BK: Cancer in
ataxia-telangiectasia patients. Cancer Genet Cytogenet. 46:9–19.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Levine AJ, Momand J and Finlay CA: The p53
tumour suppressor gene. Nature. 351:453–456. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Blons H and Laurent-Puig P: TP53 and head
and neck neoplasms. Hum Mutat. 21:252–257. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Erber R, Conradt C, Homann N, Enders C,
Finckh M, Dietz A, Weidauer H and Bosch FX: TP53 DNA contact
mutations are selectively associated with allelic loss and have a
strong clinical impact in head and neck cancer. Oncogene.
16:1671–1679. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nylander K, Dabelsteen E and Hall PA: The
p53 molecule and its prognostic role in squamous cell carcinomas of
the head and neck. J Oral Pathol Med. 29:413–425. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stransky N, Egloff AM, Tward AD, Kostic
AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C,
McKenna A, et al: The mutational landscape of head and neck
squamous cell carcinoma. Science. 333:1157–1160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Agrawal N, Frederick MJ, Pickering CR,
Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, et
al: Exome sequencing of head and neck squamous cell carcinoma
reveals inactivating mutations in NOTCH1. Science. 333:1154–1157.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Skinner HD1, Sandulache VC, Ow TJ, Meyn
RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK and Myers
JN: TP53 disruptive mutations lead to head and neck cancer
treatment failure through inhibition of radiation-induced
senescence. Clin Cancer Res. 18:290–300. 2012. View Article : Google Scholar :
|
|
21
|
Kutler DI, Auerbach AD, Satagopan J,
Giampietro PF, Batish SD, Huvos AG, Goberdhan A, Shah JP and Singh
B: High incidence of head and neck squamous cell carcinoma in
patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg.
129:106–112. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kutler DI, Singh B, Satagopan J, Batish
SD, Berwick M, Giampietro PF, Hanenberg H and Auerbach AD: A
20-year perspective on the International Fanconi Anemia Registry
(IFAR). Blood. 101:1249–1256. 2003. View Article : Google Scholar
|
|
23
|
Rosenberg PS, Socié G, Alter BP and
Gluckman E: Risk of head and neck squamous cell cancer and death in
patients with Fanconi anemia who did and did not receive
transplants. Blood. 105:67–73. 2005. View Article : Google Scholar
|
|
24
|
Walden H and Deans AJ: The Fanconi anemia
DNA repair pathway: Structural and functional insights into a
complex disorder. Annu Rev Biophys. 43:257–278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chandrasekharappa SC, Lach FP, Kimble DC,
Kamat A, Teer JK, Donovan FX, Flynn E, Sen SK, Thongthip S, Sanborn
E, et al: NISC Comparative Sequencing Program: Massively parallel
sequencing, aCGH, and RNA-Seq technologies provide a comprehensive
molecular diagnosis of Fanconi anemia. Blood. 121:e138–e148. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wreesmann VB, Estilo C, Eisele DW, Singh B
and Wang SJ: Downregulation of Fanconi anemia genes in sporadic
head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat
Spec. 69:218–225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pfeiffer J, Maier W, Ridder GJ, Zaoui K
and Birkenhäger R: LOH-profiling by SNP-mapping in a case of
multifocal head and neck cancer. World J Clin Oncol. 3:24–28. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sparano A, Quesnelle KM, Kumar MS, Wang Y,
Sylvester AJ, Feldman M, Sewell DA, Weinstein GS and Brose MS:
Genome-wide profiling of oral squamous cell carcinoma by
array-based comparative genomic hybridization. Laryngoscope.
116:735–741. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bockmühl U, Schlüns K, Schmidt S, Matthias
S and Petersen I: Chromosomal alterations during metastasis
formation of head and neck squamous cell carcinoma. Genes
Chromosomes Cancer. 33:29–35. 2002. View Article : Google Scholar
|
|
30
|
Koy S, Hauses M, Appelt H, Friedrich K,
Schackert HK and Eckelt U: Loss of expression of ZAC/LOT1 in
squamous cell carcinomas of head and neck. Head Neck. 26:338–344.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Weber F, Xu Y, Zhang L, Patocs A, Shen L,
Platzer P and Eng C: Microenvironmental genomic alterations and
clinicopathological behavior in head and neck squamous cell
carcinoma. JAMA. 297:187–195. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nawroz H, van der Riet P, Hruban RH, Koch
W, Ruppert JM and Sidransky D: Allelotype of head and neck squamous
cell carcinoma. Cancer Res. 54:1152–1155. 1994.PubMed/NCBI
|
|
33
|
Bryant HE, Schultz N, Thomas HD, Parker
KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Duan W, Gao L, Zhao W, Leon M, Sadee W,
Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, et al: Assessment of
FANCD2 nuclear foci formation in paraffin-embedded tumors: A
potential patient-enrichment strategy for treatment with DNA
interstrand crosslinking agents. Transl Res. 161:156–164. 2013.
View Article : Google Scholar
|
|
35
|
de Winter JP, Rooimans MA, van Der Weel L,
van Berkel CG, Alon N, Bosnoyan-Collins L, de Groot J, Zhi Y,
Waisfisz Q, Pronk JC, et al: The Fanconi anaemia gene FANCF encodes
a novel protein with homology to ROM. Nat Genet. 24:15–16. 2000.
View Article : Google Scholar
|
|
36
|
Ahmad SI and Kirk SH: Molecular Mechanisms
of Fanconi Anemia. Landes Bioscience/Eurekah.com; 2006
|
|
37
|
de Winter JP, van der Weel L, de Groot J,
Stone S, Waisfisz Q, Arwert F, Scheper RJ, Kruyt FA, Hoatlin ME and
Joenje H: The Fanconi anemia protein FANCF forms a nuclear complex
with FANCA, FANCC and FANCG. Hum Mol Genet. 9:2665–2674. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Taniguchi T, Tischkowitz M, Ameziane N,
Hodgson SV, Mathew CG, Joenje H, Mok SC and D'Andrea AD: Disruption
of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian
tumors. Nat Med. 9:568–574. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Olopade OI and Wei M: FANCF methylation
contributes to chemoselectivity in ovarian cancer. Cancer Cell.
3:417–420. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Marsit CJ, Liu M, Nelson HH, Posner M,
Suzuki M and Kelsey KT: Inactivation of the Fanconi anemia/BRCA
pathway in lung and oral cancers: Implications for treatment and
survival. Oncogene. 23:1000–1004. 2004. View Article : Google Scholar
|
|
41
|
Narayan G, Arias-Pulido H, Nandula SV,
Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer
L, Schneider A, et al: Promoter hypermethylation of FANCF:
Disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
Cancer Res. 64:2994–2997. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Koul S, McKiernan JM, Narayan G,
Houldsworth J, Bacik J, Dobrzynski DL, Assaad AM, Mansukhani M,
Reuter VE, Bosl GJ, et al: Role of promoter hypermethylation in
Cisplatin treatment response of male germ cell tumors. Mol Cancer.
3:162004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
de Winter JP, Waisfisz Q, Rooimans MA, van
Berkel CG, Bosnoyan-Collins L, Alon N, Carreau M, Bender O, Demuth
I, Schindler D, et al: The Fanconi anaemia group G gene FANCG is
identical with XRCC9. Nat Genet. 20:281–283. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Demuth I, Wlodarski M, Tipping AJ, Morgan
NV, de Winter JP, Thiel M, Gräsl S, Schindler D, D'Andrea AD, Altay
C, et al: Spectrum of mutations in the Fanconi anaemia group G
gene, FANCG/XRCC9. Eur J Hum Genet. 8:861–868. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gallmeier E, Calhoun ES, Rago C, Brody JR,
Cunningham SC, Hucl T, Gorospe M, Kohli M, Lengauer C and Kern SE:
Targeted disruption of FANCC and FANCG in human cancer provides a
preclinical model for specific therapeutic options.
Gastroenterology. 130:2145–2154. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Levitus M, Waisfisz Q, Godthelp BC, de
Vries Y, Hussain S, Wiegant WW, Elghalbzouri-Maghrani E,
Steltenpool J, Rooimans MA, Pals G, et al: The DNA helicase BRIP1
is defective in Fanconi anemia complementation group J. Nat Genet.
37:934–935. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
47
|
Levran O, Attwooll C, Henry RT, Milton KL,
Neveling K, Rio P, Batish SD, Kalb R, Velleuer E, Barral S, et al:
The BRCA1-interacting helicase BRIP1 is deficient in Fanconi
anemia. Nat Genet. 37:931–933. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
48
|
Litman R, Peng M, Jin Z, Zhang F, Zhang J,
Powell S, Andreassen PR and Cantor SB: BACH1 is critical for
homologous recombination and appears to be the Fanconi anemia gene
product FANCJ. Cancer Cell. 8:255–265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xie J, Peng M, Guillemette S, Quan S,
Maniatis S, Wu Y, Venkatesh A, Shaffer SA, Brosh RM Jr and Cantor
SB: FANCJ/BACH1 acetylation at lysine 1249 regulates the DNA damage
response. PLoS Genet. 8:e10027862012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cantor SB and Guillemette S: Hereditary
breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. Future
Oncol. 7:253–261. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sobin LH and Fleming ID: TNM
Classification of Malignant Tumors, fifth edition (1997). Union
Internationale Contre le Cancer and the American Joint Committee on
Cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Idbaih A, Carvalho Silva R, Crinière E,
Marie Y, Carpentier C, Boisselier B, Taillibert S, Rousseau A,
Mokhtari K, Ducray F, et al: Genomic changes in progression of
low-grade gliomas. J Neurooncol. 90:133–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
van Zeeburg HJ, Snijders PJ, Pals G,
Hermsen MA, Rooimans MA, Bagby G, Soulier J, Gluckman E, Wennerberg
J, Leemans CR, et al: Generation and molecular characterization of
head and neck squamous cell lines of fanconi anemia patients.
Cancer Res. 65:1271–1276. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nagao T1, Sugano I, Ishida Y, Tajima Y,
Munakata S, Asoh A, Yamazaki K, Muto H, Konno A, Kondo Y, et al:
Primary large-cell neuroendocrine carcinoma of the parotid gland:
immunohistochemical and molecular analysis of two cases. Mod
Pathol. 13:554–561. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tarmin L, Yin J, Zhou X, Suzuki H, Jiang
HY, Rhyu MG, Abraham JM, Krasna MJ, Cottrell J and Meltzer SJ:
Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma
and squamous cell carcinoma of the esophagus. Cancer Res.
54:6094–6096. 1994.PubMed/NCBI
|
|
56
|
Chen CH, Chang CJ, Yang WS, Chen CL and
Fann CSJ: A genome-wide scan using tree-based association analysis
for candidate loci related to fasting plasma glucose levels. BMC
Genet. 4(Suppl 1): S652003. View Article : Google Scholar
|
|
57
|
Powlesland RM, Charles AK, Malik KTA,
Reynolds PA, Pires S, Boavida M and Brown KW: Loss of
heterozygosity at 7p in Wilms' tumour development. Br J Cancer.
82:323–329. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Orsetti B, Courjal F, Cuny M, Rodriguez C
and Theillet C: 17q21–q25 aberrations in breast cancer: Combined
allelotyping and CGH analysis reveals 5 regions of allelic
imbalance among which two correspond to DNA amplification.
Oncogene. 18:6262–6270. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Indraccolo S, Tisato V, Agata S, Moserle
L, Ferrari S, Callegaro M, Persano L, Palma MD, Scaini MC, Esposito
G, et al: Establishment and characterization of xenografts and
cancer cell cultures derived from BRCA1 −/− epithelial ovarian
cancers. Eur J Cancer. 42:1475–1483. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Canzian F, Salovaara R, Hemminki A, Kristo
P, Chadwick RB, Aaltonen LA and de la Chapelle A: Semiautomated
assessment of loss of heterozygosity and replication error in
tumors. Cancer Res. 56:3331–3337. 1996.PubMed/NCBI
|
|
61
|
Cawkwell L, Bell SM, Lewis FA, Dixon MF,
Taylor GR and Quirke P: Rapid detection of allele loss in
colorectal tumours using microsatellites and fluorescent DNA
technology. Br J Cancer. 67:1262–1267. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hahn M, Wieland I, Koufaki ON, Görgens H,
Sobottka SB, Schackert G and Schackert HK: Genetic alterations of
the tumor suppressor gene PTEN/MMAC1 in human brain metastases.
Clin Cancer Res. 5:2431–2437. 1999.PubMed/NCBI
|
|
63
|
Ihaka R and Gentleman R: R: A language for
data analysis and graphics. J Comput Graph Stat. 5:299–314.
1996.
|
|
64
|
Bland JM and Altman DG: Multiple
significance tests: The Bonferroni method. BMJ. 310:1701995.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cheng PF, Dummer R and Levesque MP: Data
mining The Cancer Genome Atlas in the era of precision cancer
medicine. Swiss Med Wkly. 145:w141832015.PubMed/NCBI
|
|
66
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES, et al: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Warde-Farley D, Donaldson SL, Comes O,
Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT,
et al: The GeneMANIA prediction server: Biological network
integration for gene prioritization and predicting gene function.
Nucleic Acids Res. 38(Web Server): W214–W220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kuriakose MA, Chen WT, He ZM, Sikora AG,
Zhang P, Zhang ZY, Qiu WL, Hsu DF, McMunn-Coffran C, Brown SM, et
al: Selection and validation of differentially expressed genes in
head and neck cancer. Cell Mol Life Sci. 61:1372–1383. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hu N, Clifford RJ, Yang HH, Wang C,
Goldstein AM, Ding T, Taylor PR and Lee MP: Genome wide analysis of
DNA copy number neutral loss of heterozygosity (CNNLOH) and its
relation to gene expression in esophageal squamous cell carcinoma.
BMC Genomics. 11:5762010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhu B, Yan K, Li L, Lin M, Zhang S, He Q,
Zheng D, Yang H and Shao G: K63-linked ubiquitination of FANCG is
required for its association with the Rap80-BRCA1 complex to
modulate homologous recombination repair of DNA interstand
crosslinks. Oncogene. 34:2867–2878. 2015. View Article : Google Scholar
|
|
71
|
Forbes SA, Bindal N, Bamford S, Cole C,
Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al:
COSMIC: Mining complete cancer genomes in the Catalogue of Somatic
Mutations in Cancer. Nucleic Acids Res. 39(Database): D945–D950.
2011. View Article : Google Scholar :
|
|
72
|
Deans AJ and West SC: DNA interstrand
crosslink repair and cancer. Nat Rev Cancer. 11:467–480. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ridet A, Guillouf C, Duchaud E, Cundari E,
Fiore M, Moustacchi E and Rosselli F: Deregulated apoptosis is a
hallmark of the Fanconi anemia syndrome. Cancer Res. 57:1722–1730.
1997.PubMed/NCBI
|
|
74
|
Beder LB, Gunduz M, Ouchida M, Fukushima
K, Gunduz E, Ito S, Sakai A, Nagai N, Nishizaki K and Shimizu K:
Genome-wide analyses on loss of heterozygosity in head and neck
squamous cell carcinomas. Lab Invest. 83:99–105. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
McHugh PJ, Spanswick VJ and Hartley JA:
Repair of DNA inter-strand crosslinks: Molecular mechanisms and
clinical relevance. Lancet Oncol. 2:483–490. 2001. View Article : Google Scholar
|
|
76
|
Bridge WL, Vandenberg CJ, Franklin RJ and
Hiom K: The BRIP1 helicase functions independently of BRCA1 in the
Fanconi anemia pathway for DNA crosslink repair. Nat Genet.
37:953–957. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hoffmann M, Görögh T, Gottschlich S,
Lohrey C, Rittgen W, Ambrosch P, Schwarz E and Kahn T: Human
papillomaviruses in head and neck cancer: 8 year-survival-analysis
of 73 patients. Cancer Lett. 218:199–206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Sticht C, Hofele C, Flechtenmacher C,
Bosch FX, Freier K, Lichter P and Joos S: Amplification of Cyclin
L1 is associated with lymph node metastases in head and neck
squamous cell carcinoma (HNSCC). Br J Cancer. 92:770–774. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Hashemi R and Commenges D: Correction of
the p-value after multiple tests in a Cox proportional hazard
model. Lifetime Data Anal. 8:335–348. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Bryne M, Koppang HS, Lilleng R, Stene T,
Bang G and Dabelsteen E: New malignancy grading is a better
prognostic indicator than Broders' grading in oral squamous cell
carcinomas. J Oral Pathol Med. 18:432–437. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kristensen GB, Abeler VM, Risberg B, Trop
C and Bryne M: Tumor size, depth of invasion, and grading of the
invasive tumor front are the main prognostic factors in early
squamous cell cervical carcinoma. Gynecol Oncol. 74:245–251. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Bryne M, Koppang HS, Lilleng R and
Kjaerheim A: Malignancy grading of the deep invasive margins of
oral squamous cell carcinomas has high prognostic value. J Pathol.
166:375–381. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Lim SL, Smith P, Syed N, Coens C, Wong H,
van der Burg M, Szlosarek P, Crook T and Green JA: Promoter
hypermethylation of FANCF and outcome in advanced ovarian cancer.
Br J Cancer. 98:1452–1456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Begg AC: Predicting recurrence after
radiotherapy in head and neck cancer. Semin Radiat Oncol.
22:108–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Curtin NJ and Szabo C: Therapeutic
applications of PARP inhibitors: Anticancer therapy and beyond. Mol
Aspects Med. 34:1217–1256. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
McCabe N, Turner NC, Lord CJ, Kluzek K,
Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka
MZ, et al: Deficiency in the repair of DNA damage by homologous
recombination and sensitivity to poly(ADP-ribose) polymerase
inhibition. Cancer Res. 66:8109–8115. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Nowsheen S, Bonner JA and Yang ES: The
poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces
radiation-induced nuclear EGFR and augments head and neck tumor
response to radiotherapy. Radiother Oncol. 99:331–338. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Khan K, Araki K, Wang D, Li G, Li X, Zhang
J, Xu W, Hoover RK, Lauter S, O'Malley B Jr, et al: Head and neck
cancer radiosensitization by the novel poly(ADP-ribose) polymerase
inhibitor GPI-15427. Head Neck. 32:381–391. 2010.
|
|
89
|
Li Y, Zhao L, Sun H, Yu J, Li N, Liang J,
Wang Y, He M, Bai X, Yu Z, et al: Gene silencing of FANCF
potentiates the sensitivity to mitoxantrone through activation of
JNK and p38 signal pathways in breast cancer cells. PLoS One.
7:e442542012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Yu J, Zhao L, Li Y, Li N, He M, Bai X, Yu
Z, Zheng Z, Mi X, Wang E, et al: Silencing of fanconi anemia
complementation group f exhibits potent chemosensitization of
mitomycin C activity in breast cancer cells. J Breast Cancer.
16:291–299. 2013. View Article : Google Scholar : PubMed/NCBI
|
